Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page
- Check5 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed the previous funding notice and Revision: v3.4.1.SummaryDifference0.3%

- Check41 days agoChange DetectedA site-wide notice about government funding status was added, advising users to check cc.nih.gov and opm.gov for updates. The page version was updated to Revision: v3.4.1, replacing v3.4.0.SummaryDifference0.3%

- Check48 days agoChange DetectedGlossary toggle added and study-record metadata labels updated (including capitalization tweaks to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data') with Revision: v3.4.0. No core content, outcomes, or eligibility criteria were changed.SummaryDifference0.2%

- Check62 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedAdded a comprehensive list of study locations across the United States and abroad (including numerous US states and international regions) and updated the document revision to v3.3.3.SummaryDifference2%

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.